Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

UGN-201

Other · developed by UroGen Pharma

Phase 1 Most advanced trial (none active)
URGN Developer
1 Registered trials

What is UGN-201?

UGN-201 is a drug administered intravesically (directly into the bladder) and studied in non-muscle invasive bladder cancer, including carcinoma in situ and recurrent urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
UroGen Pharma Ltd. (URGN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05375903 Phase 1 Non-muscle Invasive Bladder Cancer Completed URGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerCarcinoma in Situ of BladderNMIBCNon-muscle Invasive Bladder CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent

More from UroGen Pharma

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the URGN page.

Follow URGN, the company behind UGN-201

See URGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

URGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.